[February 20, 2017]

Vulvovaginal Candidiasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 - Research and Markets

Research and Markets has announced the addition of the "Vulvovaginal Candidiasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017" drug pipelines to their offering.

Vulvovaginal Candidiasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

A key objective of the Vulvovaginal Candidiasis Report is to understand the market and pipeline status of the drugs around the Vulvovaginal Candidiasis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline straegies. The Report provides the historical and forecasted sales of the drugs till 2018.

The Vulvovaginal Candidiasis Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Vulvovaginal Candidiasis.

While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Key Topics Covered:

1. Indication Overview

2. Market Drugs Landscape

3. Global API Manufacturers Assessment

4. Phase III Drugs Landscape

5. Drugs Market Data and Forecasted Sales Figure-2018

6. Marketed Drugs for Vulvovaginal Candidiasis

7. Phase III Drugs for Vulvovaginal Candidiasis

8. Discontinued Drugs for Vulvovaginal Candidiasis

9. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/kqdzth/vulvovaginal

View source version on businesswire.com: http://www.businesswire.com/news/home/20170220005388/en/

[ Back To TMCnet.com's Homepage ]